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The host innate immune response is an important deterrent of severe viral infection in humans and animals.
Nuclear import factors function as key gatekeepers that regulate the transport of innate immune regulatory
cargo to the nucleus of cells to activate the antiviral response. Using severe acute respiratory syndrome
coronavirus (SARS-CoV) as a model, we demonstrate that SARS-COV ORF6 protein is localized to the
endoplasmic reticulum (ER)/Golgi membrane in infected cells, where it binds to and disrupts nuclear import
complex formation by tethering karyopherin alpha 2 and karyopherin beta 1 to the membrane. Retention of
import factors at the ER/Golgi membrane leads to a loss of STAT1 transport into the nucleus in response to
interferon signaling, thus blocking the expression of STAT1-activated genes that establish an antiviral state.
We mapped the region of ORF6, which binds karyopherin alpha 2, to the C terminus of ORF6 and show that
mutations in the C terminus no longer bind karyopherin alpha 2 or block the nuclear import of STAT1. We also
show that N-terminal deletions of karyopherin alpha 2 that no longer bind to karyopherin beta 1 still retain
ORF6 binding activity but no longer block STAT1 nuclear import. Recombinant SARS-CoV lacking ORF6 did
not tether karyopherin alpha 2 to the ER/Golgi membrane and allowed the import of the STAT1 complex into
the nucleus. We discuss the likely implications of these data on SARS-CoV replication and pathogenesis.
Severe acute respiratory syndrome (SARS) is a potentially
fatal disease that likely originated in the Guandong Province of
China in the fall of 2002 (14, 26). The global outbreak infected
more than 8,000 people and resulted in about 800 deaths, with
economic losses in the tens of billions of dollars (www.who.int
/csr/sars/en/). The disease is caused by a new human corona-
virus (CoV), designated SARS-CoV, that likely evolved from
closely related strains in civet cats, raccoon dogs, and bats (28,
45). Low-level seropositivity in archived human sera is sugges-
tive of multiple introductions into human populations prior to
2002 (63). The underlying mechanisms governing the high
mortality rates during SARS-CoV infection remain largely un-
known.
SARS-CoV is a single-stranded positive-polarity enveloped
virus. The genome is approximately 29.7 kb long with the 5
two-thirds of the genome encoding proteins important for rep-
licase function and the 3 one-third of the genome encoding
structural proteins and group-specific (accessory) proteins.
The accessory open reading frames (ORFs) are unique to each
different strain of CoV and are predicted to encode functions
important in pathogenesis (11). Among the SARS-CoV acces-
sory ORFs, ORF3a, ORF6, ORF7a, and ORF7b are not es-
sential for in vitro or in vivo replication or release of infectious
viruses (62), although each one is reported to be incorporated
into virions (22, 23, 50, 54).
An important host defense against invading pathogens is the
innate immune system. The innate immune system consists of
secreted cytokines, intracellular signaling pathways, and the
expression of type I interferon (IFN) that signals to neighbor-
ing cells to induce an antiviral state (reviewed in reference 16).
SARS-CoV has been shown to affect IFN regulatory factor 3
(IRF3) trafficking and activation during infection (55). In mu-
rine models, SARS-CoV infection is cleared normally from
infected CD1/ and RAG1/ mice but not STAT1/ mice,
suggesting that innate immunity coordinates an effective anti-
viral response, and protection in these models does not require
adaptive immunity (17, 21).
Interactions between the adaptive immune system and CoVs
have been studied with great detail, yet the role of innate
immunity and the virus-host interactions that modulate the
innate immune response during infection are less well charac-
terized (5, 7, 27). Taguchi and Siddell showed that different
strains of mouse hepatitis virus (MHV) were differentially sus-
ceptible to type I IFN and hypothesized that this difference
influenced pathogenic outcomes (56). Ye et al. showed previ-
ously that the MHV nucleocapsid (N) protein interacts with
protein kinase R and 2,5-oligoadenylate synthase machinery
to inhibit viral RNA degradation (60). Kamitani et al. demon-
strated that SARS nsp1 protein expression led to the degrada-
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tion of cellular RNA messages by an unknown mechanism,
including IFN- mRNA, suggesting a possible role in antago-
nizing type I IFN induction (24). In addition, Kopecky-Brom-
berg et al. demonstrated that different arms of the type I IFN
induction pathway can be blocked by the expression of SARS-
CoV ORF3b, ORF6, and N protein in vitro (25).
As type I interferon (IFN-/) is secreted from a cell,
IFN-/ can bind to the IFN-/ receptor on the surface of
neighboring cells or the same cell in a paracrine or autocrine
fashion. Binding leads to the activation of the receptor, recruit-
ment of JAK kinase, and phosphorylation of STAT1 via JAK.
Phosphorylation induces STAT1 to form a complex with
STAT2 and IRF9, forming the interferon-stimulated gene fac-
tor 3 (ISGF3) complex. ISGF3 binds import factor karyo-
pherin alpha 1 (KPNA1) and recruits karyopherin beta 1
(KPNB1) for transport into the nucleus (35), where STAT1
acts as a transcription factor for many IFN-induced genes that
establish the antiviral state (34, 36). The mechanism by which
ORF6 blocks STAT1 transport into the nucleus is not known,
nor has the function of ORF6 been established in the context
of virus infection.
Multiple levels of regulation occur at the level of protein
import of ISGF3 to the nucleus. After being appropriately
phosphorylated, STAT1 interacts with the ISGF3 complex,
exposing an unusual nuclear localization signal (NLS) on its
surface for the recruitment of a specific karyopherin, KPNA1
(34, 51). Each of the karyopherins (designated KPNA1 to
KPNA4) recognizes NLS sites in distinct yet sometimes over-
lapping sets of protein cargo destined for transport into the
nucleus (reviewed in reference 8). After binding cargo, an
N-terminal repeat domain termed the importin beta binding
site in each KPNA engages KPNB1, which chaperones each
KPNA/cargo complex through the nuclear pore (18, 38). Ebola
virus VP24 has been shown to affect STAT1 binding to KPNA1
by blocking the binding site on KPNA1 and thus blocking
STAT1 nuclear import and signaling (47).
Previous studies by our group indicated that ORF6 expres-
sion from plasmids blocked STAT1 translocation to the nu-
cleus (25). In this paper, we demonstrate that ORF6 sequesters
host nuclear import factors into the rough endoplasmic retic-
ulum (ER) (rER)/Golgi membrane, thus blocking the nuclear
import of STAT1, and functions as an IFN antagonist in the
context of SARS-CoV infection.
MATERIALS AND METHODS
SARS infections. Vero, MA104, 293, and Caco2 cells were infected with an
infectious clone of SARS CoV strain Urbani (icSARS) (61), SARS strain Urbani
(GenBank accession number AY2787421), or Sendai virus (SeV) (ATCC VR-
907) for 18 h at a multiplicity of infection (MOI) of 5. Vero cells (ATCC
CRL-1586) (African green monkey kidney cells), MA104 cells (ATCC CRL-
2378.1) (African green monkey kidney cells), HEK293 cells (ATCC CRL-11268)
(human embryonic kidney cells), and Caco2 cells (ATCC CRL-2102) (human
intestinal epithelial cells) were grown in standard growth medium according to
ATCC recommendations. Growth medium was harvested for an IFN bioassay
(see below), cells were treated with TRIzol (Invitrogen, Carlsbad, CA), and
RNA was extracted according to the manufacturer’s directions.
Plasmids. SARS-CoV ORF6 was cloned using icSARS as a template for PCR
primers. The ORF was amplified using forward primer 1 (5-ACGTCCCGGGTG
GATAATCTAACTCCA-3) and reverse primer 5-GGCCGAATTCACCATGTT
TCATCTAGTTGACTT-3. PCR products were digested with EcoRI and XmaI
and cloned into pCAGGS-HA containing a hemagglutinin (HA) tag at the XmaI
site. For ORF6 59 to 63 Ala constructs, forward primer 1 was used with reverse
primers 5-CCCGGGTTCATCATCTAACTCCGAATAATTCTTCTT-3 and
5-ACGTCCCGGGTGCCGCTGCAGCTGCCATAGGTTCTTCATC-3, respec-
tively. For ORF6 54 to 58 Ala, two rounds of PCR were used. The first step involved
forward primer 1 as described above and reverse primer 5-TGCCGCTGCAGCT
GCATCTAACTCCGAATAATTCT-3. The PCR product was then reamplified
using the forward primer 1 and reverse primer 5-ACGTCCCGGGTGGATAATC
TAACTCTGCCGCTGCAGC-3. For ORF6 49 to 53 Ala, two rounds of PCR were
used. The first step used forward primer 1 and reverse primer 5-TTCATCTGCC
GCTGCAGCTGCATTCTTCTTAGTTA-3. The PCR product was then reampli-
fied using forward primer 1 and reverse primer 5-ACGTCCCGGGTGGATAAT
CTAACTCCATAGGTTCTTCATCTGCCGCTGC-3. KPNA2N was cloned
using forward primer 5-CGATAAGGCGGCCGCGATGATTGTCAAAGGCAT
AAATAGC-3 and reverse primer 5-CATCAATCACAACCTGAGTCTGTTCA
TCTG-3. After PCR amplification, the amplicon was cloned into parent vector
pCAGGS-KPNA2/FLAG using NotI and PstI.
IFN bioassay and IFN- reverse transcription (RT)-PCR. MA104 cells were
infected with icSARS or SeV at an MOI of 5. Medium was removed from the
cells for the bioassay, and cells were treated with TRIzol for RNA extraction.
The bioassay was described previously for use with human type I IFN and A549
cells (52). Briefly, the pH of the medium was lowered to 2 with 2 N HCl and
incubated at 4°C overnight. The pH of the medium was then adjusted to pH 7
with NaOH. One hundred microliters of the medium was then added to A549
cells plated in a 96-well plate and incubated for 24 h. After Encephalomyocar-
ditis virus infection for 1 h, the cultures were incubated for 24 h before the plates
were scored for cytopathic effect.
Isolated RNA was converted to cDNA with Superscript II (Invitrogen, Carls-
bad, CA) and random hexamers and used for a PCR for GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) and IFN-. GAPDH-specific primers were
5-GTCTTCACCACCATGGAGAAGGCTGGGGCT-3 and 5-ACAGCCTT
GGCAGCGCCAGTAGAGGCAGGG-3, while IFN- primers were 5-GACG
CCGCATTGACCATCTA-3 and 5-CCTTAGGATTTCCACTCTGACT-3.
STAT1 localization. The same procedure was used for transfections of both
293 and Vero cells in culture. Cells were grown on glass coverslips in 24-well
plates. Five hundred nanograms of STAT1/green fluorescent protein (GFP)
plasmid, 500 ng of ORF6 plasmid, or various derivative constructs and Fugene 6
(Roche, Indianapolis, IN) were used for transfections according to the manu-
facturer’s directions. At 24 h after transfection, cells were treated with 100 IU/ml
of IFN- (Calbiochem, San Diego, CA) for 1 h. Cells were fixed with 4%
paraformaldehyde (PFA) and imaged in the Microscopy Service Laboratory
(University of North Carolina at Chapel Hill) using a Zeiss LSM5 Pa confocal
laser scanning microscope.
Immunofluorescence. HA-tagged ORF6, Flag-tagged KPNA (a gift of Megan
Shaw, Mount Sinai Medical Center), and Flag-tagged KPNB1 (a gift of Nancy
Reich, Stony Brook University, Stony Brook, NY) plasmids were transfected as
described above, and cells were fixed with 4% PFA. Fixed cells were incubated
with rabbit anti-HA antibody (Sigma-Aldrich, St. Louis, MO) and mouse anti-
Flag M2 antibody (Sigma-Aldrich, St. Louis, MO). Coverslips were incubated
with secondary antibodies: Alexa Fluor 488-, 546-, or 633-conjugated goat anti-
rabbit antibody (Molecular Probes) and Alexa Fluor 488-, 546-, or 633-conju-
gated goat anti-mouse antibody (Molecular Probes). Confocal imaging was per-
formed in the Microscopy Service Laboratory (University of North Carolina at
Chapel Hill) using a Zeiss LSM5 Pa confocal laser scanning microscope.
Flag immunoprecipitations. Flag-tagged karyopherins were transfected as de-
scribed above. After 24 h of expression, cells were lysed in lysis buffer (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40), the extract was centrifuged for 10
min at 4°C, and the supernatant was removed. Twenty-five microliters of washed
EZ View Red Anti-Flag M2 Affinity Gel beads (catalog number F2426; Sigma,
St. Louis, MO) was added to each extract and rotated overnight at 4°C. The
extract was then washed three times with lysis buffer and resuspended in sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) loading buffer
before boiling and electrophoresis.
Split YFP localization. KPNA2 and ORF6 were cloned into a “Venus” split
yellow fluorescent protein (YFP) plasmid by PCR amplification and the restric-
tion enzymes BspEI/Xba1 and NotI/ClaI, respectively (plasmids were a gift of
Stephen Michnick, University of Montreal). Primers used for the amplification of
KPNA2 cDNA were 5-ACTGTCCGGAATGTCCACCAACGAGAATGC-3
and 5-GTCAAGATCTCTAAAAGTTAAAGGTCCCAGGAGCCCCATC-3,
while primers used for the amplification of ORF6 cDNA were 5-ACTGGCG
GCCGCACCATGTTTCATCTTGTTGACTT-3 and 5-CAGTATCGATTGG
ATAATCTAACTCCA-3. Plasmids were transfected as described above and
visualized using a Zeiss Confocal microscope and a YFP-specific filter.
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RESULTS
SARS does not induce IFN in infected cells. Cultures of cells
were infected with icSARS (infectious clone of SARS strain
Urbani), SARS strain Urbani, or SeV at an MOI of 5 and
evaluated for IFN induction by the detection of IFN- tran-
scripts and secretion of type I IFN into the medium. We found
robust levels of IFN- RNA transcripts in MA104 cells follow-
ing SeV infection, but not SARS-CoV infection, using RT-
PCR (Fig. 1A). Media from infected MA104 cells were ana-
lyzed for the presence of secreted IFN- protein by IFN
bioassay. Type I IFNs were not detected in the medium from
SARS infections of MA104 cells (Fig. 1B). While similar re-
sults were also seen in SARS-CoV-infected 293 cells, human
airway epithelial cells, and Caco2 cells, robust levels of type I
interferon were secreted in SeV-infected cultures of each cell
line (data not shown).
SARSORF6 does not block STAT1 nuclear translocation.
We previously showed that ORF6 expressed from a plasmid
blocks the nuclear translocation of STAT1 after IFN- treat-
ment (25). To determine if STAT1 transport was blocked in
the context of virus infection, cultures of Vero cells were trans-
fected with STAT1/GFP and then infected with wild-type
icSARS or icSARS which lacks ORF6 (icSARSORF6) (62).
Following virus infection, STAT1 was seen localized in the
cytoplasm at 12 h postinfection (data not shown), in agreement
with our data showing that SARS-CoV does not induce IFN
and thus does not induce STAT1 nuclear import. After treat-
ment of uninfected cultures with IFN-, STAT1 was translo-
cated to the nucleus within 60 min. Following IFN- treatment
of a wild-type icSARS-infected culture, STAT1 was not trans-
located into the nucleus (Fig. 2A, top). Under identical condi-
tions, STAT1/GFP was successfully transported into the nucleus
of icSARSORF6-infected cells (Fig. 2A, middle), demonstrat-
ing that ORF6 expression may be responsible for the nuclear
trafficking block of STAT1 during virus infection. In agreement
with these findings, the icSARSORF6 deletion phenotype was
reversed by providing ORF6 in trans via an expression plasmid
(pORF6) prior to infection and IFN- treatment (Fig. 2A, bot-
tom). As a control, recombinant icSARS viruses lacking either
ORF3a or ORF7ab prevented the translocation of STAT1/GFP
to the nucleus after IFN treatment, as seen for the wild-type
icSARS virus (data not shown).
KPNA1 interacts with ORF6. Previous studies indicated that
ORF6 does not prevent STAT1 phosphorylation or dimeriza-
tion (25) or degrade IFN-/ receptors in infected cells (data
not shown), suggesting a novel mechanism of action. Activated
STAT1 (and the ISGF3 complex) is normally translocated into
the nucleus by binding KPNA1, which then recruits and binds
KPNB1. Together, the STAT1:KPNA1:KPNB1 complex is im-
ported into the nucleus (34). As Ebola virus VP24 was shown
to bind KPNA1 and block its interaction with STAT1 (47), it is
possible that ORF6 may block STAT1’s nuclear import by
interacting with nuclear import factors. To determine if karyo-
pherin interactions were altered in the STAT1 signaling path-
way, we transfected Flag-tagged KPNA1, KPNA2, KPNA3,
and KPNA4 into 293 cells and assayed their interactions with
STAT1 and STAT2 in the presence or absence of IFN- treat-
ment. Transfected 293 cells were either mock treated or
treated with IFN- for 30 min. Extracts were immunoprecipi-
tated with anti-Flag antibody and run on SDS-PAGE gels for
analysis. We found that STAT1 and STAT2 interacted with
KPNA1 and not KPNA2, KPNA3, or KPNA4 specifically after
IFN- treatment, confirming previously described work (Fig.
3A) (34).
To test the hypothesis that ORF6 may interact with a KPNA,
coimmunoprecipitations were performed following single
transfections and cotransfections of 293 cells. At 24 h after
transfection of HA-tagged ORF6 with each Flag-tagged
KPNA, proteins were coimmunoprecipitated with anti-Flag
antibody and separated on an SDS-PAGE gel. We found that
ORF6 was specifically coimmunoprecipitated with KPNA2 but
not with KPNA1, KPNA3, or KPNA4 (Fig. 3B, top). Interest-
ingly, STAT1 normally interacts with KPNA1 during normal
IFN-induced nuclear transport and not with KPNA2.
Since ORF6 is an ER/Golgi membrane protein and interacts
with KPNA2 by immunoprecipitation, we hypothesized that
KPNA2, which is normally distributed in the cytoplasm, may
become membrane associated, resulting in a loss of nuclear
localization. To confirm the biochemical association, we co-
transfected Flag-tagged KPNA1, KPNA2, KPNA3, and KPNA4
into Vero cells with HA-tagged ORF6 and determined the
localization of each protein. By confocal microscopy, the ex-
pression of KPNA1, KPNA2, KPNA3, and KPNA4 resulted in
a predominantly nuclear localization, a phenotype typically
observed following expression from plasmids (Fig. 3C) (53).
Following cotransfection with ORF6, KPNA1, KPNA3, and
KPNA4 were still localized to the nucleus (Fig. 3D). In agree-
ment with our immunoprecipitation data, KPNA2 was colocal-
FIG. 1. SARS-CoV encodes an IFN antagonist. (A) MA104 cells
were infected with SARS and SeV or mock infected for 12 h. Extracted
RNA was analyzed by RT-PCR for the induction of IFN- mRNA.
RT-PCR-amplified GAPDH transcripts are shown as a loading con-
trol. (B) Media from icSARS-, Urbani virus-, and SeV-infected
MA104 cells were analyzed for secreted type I IFN across a time
course of infection. An IFN bioassay (as described in Materials and
Methods) was used to analyze the amount of type I IFN secreted from
infected cells. The dotted line is the minimal level of detection for the
assay.
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ized with ORF6 on the ER/Golgi membrane, further support-
ing an interaction between ORF6 and KPNA2.
KPNA2 and ORF6 interact in vivo. To further demonstrate
an intimate in vivo interaction between ORF6 and KPNA2, we
utilized the enhanced Venus split YFP system (40). In this
system, the N- and C-terminal halves of YFP are indepen-
dently fused to two putative interacting proteins. If these pro-
teins interact, that interaction event brings the two YFP halves
in intimate proximity, which folds and reconstitutes the YFP
protein, leading to fluorescence. The N terminus of YFP was
fused in frame to KPNA2, and the C terminus of YFP was
fused in frame to ORF6. Each construct was transfected into
Vero cells for 24 h prior to visualization. Positive-control
leucine zipper plasmids successfully reconstituted YFP fluo-
rescence as reported previously (40) (Fig. 4A). Transfection of
the KPNA2 or ORF6 construct independently did not result in
YFP fluorescence (Fig. 4B and C). As a control, KPNA2 and
ORF6 fusions were transfected with their complementary
leucine zipper/YFP plasmids, and no fluorescence was seen,
demonstrating that interacting partners were needed for fluo-
rescence (Fig. 4D). Cotransfection of KPNA2/YFP-N and
ORF6/YFP-C resulted in robust YFP fluorescence localized to
the ER/Golgi membrane (Fig. 4E), confirming an in vivo in-
teraction between KPNA2 and ORF6.
SARS-CoV, but not SARSORF6, retains KPNA2 at the
ER/Golgi membrane. Since KPNA2 nuclear localization was
altered in ORF6-transfected cells, we next determined whether
KPNA2 localization was also altered following SARS-CoV in-
fection. Utilizing wild-type icSARS and SARSORF6 recom-
binant viruses, we infected Vero cells that had been previously
transfected with Flag-tagged KPNA1 or KPNA2. Eight hours
postinfection, cells were fixed and analyzed by confocal micros-
copy for the localization of KPNA1 and KPNA2 in SARS-
infected cells. Using immunofluorescence for the SARS N
protein as a marker to identify icSARS-CoV- and icSARS
ORF6-infected cells, KPNA1 in control and virus-infected cells
remains localized predominantly in the nucleus, supporting
data from previous studies showing that KPNA1 is not inter-
acting directly with ORF6 (Fig. 4F). In contrast, a clear differ-
ence in KPNA2 localization was seen in wild-type- and
icSARSORF6-infected cells. In wild-type virus-infected cells
expressing ORF6, KPNA2 was localized to the rER/Golgi.
In cultures infected with recombinant virus lacking ORF6,
KPNA2 was localized predominantly to the nucleus (Fig. 4F).
Taken together, these data support a direct interaction be-
tween KPNA2 and ORF6 in the context of virus infection.
KPNB1 relocalizes to the ER/Golgi membrane when ORF6
is present. Although ORF6 causes a relocalization of KPNA2
FIG. 2. STAT1 localization during SARS infection. STAT1/GFP plasmid was transfected into Vero cells, and its localization was assayed after
SARS infection. At 24 h posttransfection, cells were infected with either icSARS (top) or icSARSORF6 (middle) at an MOI of 3 for 12 h. Before
fixation in 4% PFA, cells were treated with 100 IU of IFN- for 1 h. The cells in the bottom panels were cotransfected with STAT1/GFP and
HA-ORF6 prior to infection with icSARSORF6. Cells were then labeled with anti-SARS spike antibody to visualize the SARS-infected cells or
anti-HA antibody (to visualize the transfected cells) and an Alexa 546-conjugated secondary antibody. Cells were visualized by using a confocal
microscope.
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FIG. 3. ORF6 affects localization of KPNA2. (A) 293 cells were transfected with Flag-tagged karyopherin plasmids. At 24 h posttransfection,
half of the cells were treated with 100 IU of IFN- for 30 min, and protein was harvested as described in Materials and Methods. Proteins were
then immunoprecipitated (IP) with anti-Flag (Flag) M2 antibodies and run on an SDS-PAGE gel before being transferred for Western blotting.
Blots were probed with STAT1, STAT2, or Flag antibodies.  indicates treatment with 100 IU/ml of IFN-. (B) Immunoprecipitations were
performed on 293 cells cotransfected with each Flag-tagged karyopherin and HA-tagged ORF6. Lysates were prepared and immunoprecipitated
as described in Materials and Methods. The top panel was probed with anti-HA antibody to visualize ORF6, and the bottom panel was probed
with anti-KPNB1. A1, KPNA1; A2, KPNA2; A3, KPNA3; A4, KPNA4. (C) Vero cells were transfected with Flag-tagged KPNA plasmids. At 24 h
posttransfection, cells were fixed and labeled with anti-Flag antibody. (D) Vero cells were cotransfected with Flag-tagged KPNA plasmids and
HA-ORF6 plasmid. At 24 h posttransfection, cells were fixed and labeled with anti-Flag antibody and anti-HA antibody. Anti-Flag antibody was
visualized with Alexa Fluor 488-conjugated secondary antibody, and anti-HA antibody was visualized with Alexa Fluor 546-conjugated secondary
antibody. Note the overlapping localization of ORF6 and KPNA2.
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FIG. 4. Interaction between KPNA2 and ORF6 in vivo. The top panel shows a schematic of the split YFP assay. The cargo is fused to each
half of YFP. When the cargo interacts, the YFP halves are brought together to re-form and fluoresce. Vero cells were transfected with YFP
plasmids, and 24 h after transfection, YFP fluorescence was visualized on a confocal microscope using a YFP filter. (A) YFP-N/leucine zipper (LZ)
and YFP-C/leucine zipper (positive controls). (B) YFP-N/KPNA2. (C) YFP-C/ORF6. (D) YFP-N/leucine zipper plus YFP-C/ORF6. (E) YFP-
N/KPNA2 and YFP-C/ORF6. (F) Karyopherin localization during SARS infection. Vero cells were transfected with Flag-tagged KPNA1 or
KPNA2 24 h prior to infection with either icSARS or icSARSORF6. Cells were fixed in 4% PFA prior to antibody staining. SARS mouse anti-N
antibody (N) was used to localize SARS-infected cells, and rabbit anti-Flag antibody was used to localize karyopherins. Mouse anti-N antibody
was visualized with Alexa Fluor 488-conjugated secondary antibody, and anti-Flag antibody was visualized with Alexa Fluor 546-conjugated
secondary antibody.
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from the cytosol to the ER/Golgi membrane, KPNA2 is not
directly involved in the translocation of the STAT1:STAT2:
IRF9 (ISGF3) complex into the nucleus; rather, KPNA1 in-
teracts with KPNB1 to initiate ISGF3’s nuclear localization. If
KPNA2 interacted directly with KPNB1, tethering it to the
ER/Golgi complex, this association might subsequently limit
KPNB1’s interaction with the STAT1 complex via KPNA1. To
test this hypothesis, 293 cells were transfected with the karyo-
pherin plasmids for 24 h, and coimmunoprecipitations were
performed with antibodies directed against the Flag-tagged
KPNAs. Western blots were probed with anti-KPNB1 antibody
to determine if KPNB1 was coimmunoprecipitated with each
KPNA (Fig. 3B, bottom). We find that KPNB1 interacts with
each of the four KPNAs tested, confirming data from previ-
ously reported studies (43).
We have shown that ORF6 interacts with KPNA2 on the
ER/Golgi membrane. If this interaction is similar to KPNA2
binding an NLS on a protein destined for the nucleus, then
following KPNA2’s binding to an NLS, a conformational change
occurs in KPNA2, revealing the N-terminal importin beta binding
domain that binds KPNB1 for nuclear import (9). As ORF6 is
membrane bound, KPNA2 binding to ORF6 may present the
importin beta binding domain for KPNB1 binding and allow
KPNB1 to be tethered to the ER/Golgi membrane as well.
To determine whether KPNB1 subcellular localization was
altered in ORF6-transfected cells, HA-tagged ORF6 and Flag-
tagged KPNB1 were transfected into Vero cells, and the
tagged proteins were localized. We find that the KPNB1 dis-
tribution was diffusely cytoplasmic and nuclear in the absence
of ORF6, consistent with data from previous reports in the
literature (33) (Fig. 5A). However, in ORF6-cotransfected cul-
tures, KPNB1 colocalized with ORF6 to the ER/Golgi mem-
brane and was localized mostly to the cytoplasm and not the
nucleus.
To further prove an interaction in vivo, we transfected
ORF6 and each KPNA into 293 cells and evaluated whether
FIG. 5. ORF6 interacts with KPNB1. (A) ORF6 colocalization with KPNB1. Vero cells were transfected with Flag-tagged KPNB1 and
HA-ORF6. At 24 h posttransfection, cells were fixed and stained. Cells were incubated with mouse anti-HA (HA) and rabbit anti-Flag antibodies.
Anti-Flag antibody was visualized with Alexa Fluor 546-conjugated secondary antibody, and anti-HA antibody was visualized with Alexa Fluor
488-conjugated secondary antibody. Coverslips were visualized with a Zeiss confocal microscope. (B) 293 cells were transfected with HA-tagged
ORF6 and Flag-tagged KPNA1, KPNA2, KPNA3, or KPNA4. Cells were lysed 24 h posttransfection and immunoprecipitated (IP) with anti-HA
antibody. Proteins were separated on a 4 to 12% SDS PAGE gel and analyzed by Western blot (WB) probing with anti-HA, anti-Flag, and
anti-KPNB1 antibody.
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KPNB1 was coimmunoprecipitated with the ORF6:KPNA2
complex by immunoprecipitation with anti-HA antibody. We
found that KPNB1 was no longer associated with each of the
four KPNAs as seen in Fig. 3B but rather was coimmunopre-
cipitated only with the KPNA2:ORF6 complex (Fig. 5B, lane
6). These data support the hypothesis that ORF6 binds
KPNA2 as cargo, activating KPNA2’s KPNB1 binding domain
and tethering KPNB1 to the ORF6:KPNA2 complex on the
rER/Golgi membrane.
A KPNA2 mutant binds ORF6 but not KPNB1. As described
above, KPNAs bind to KPNB1 via their N-terminal domain,
called the importin beta binding site. If the KPNA2:ORF6
complex recruits KPNB1, then KPNA2 with a deletion of its
importin beta binding site would no longer be able to bind
KPNB1 in either the presence or absence of ORF6. To test this
hypothesis, we produced an N-terminal deletion of KPNA2,
deleting amino acids 2 to 80 (KPNA2N). 293 cells were trans-
fected with either Flag-tagged wild-type KPNA1, KPNA2, or
KPNA2N in addition to HA-tagged ORF6. At 24 h posttrans-
fection, cells were treated with IFN- for 60 min and then
lysed, and anti-Flag immunoprecipitations were performed. As
shown in Fig. 3A, KPNA1 binds to STAT1 only after treatment
with IFN- (Fig. 6A, lane 2). Consistent with previous findings,
this interaction is independent of ORF6 expression (Fig. 6A,
lanes 9 and 10), since in the presence of ORF6, KPNA1 still
binds STAT1 after IFN- treatment. Moreover, Western blot-
ting of the Flag immunoprecipitates for KPNB1 shows that in
the absence of ORF6, KPNB1 associates with KPNA1 and
KPNA2 but not KPNA2N, confirming that the importin beta
binding site of KPNA2 is necessary for KPNB1 binding. In the
presence of ORF6, KPNA1 no longer binds KPNB1; however,
under identical conditions, KPNA2 binds KPNB1 efficiently
(Fig. 6A, lanes 9 and 11). As predicted, KPNA2N binds
ORF6 but no longer interacts with KPNB1 (Fig. 6A, lane 13).
Together, these results indicate that ORF6 binds KPNA2 as
well as KPNB1; however, this binding does not reduce the
KPNA1:STAT1 complex in the cell, and it reduces only the
KPNA1:STAT1:KPNB1 complex.
While immunoprecipitations provide strong biochemical
support for in vitro interactions, we next examined how these
interactions would affect STAT1 localization in a cell. To that
end, we transfected STAT1/GFP with the wild-type and mu-
tant KPNA constructs in the presence or absence of ORF6 to
determine how STAT1 localization was affected following
IFN- treatment. First, we tested the effects of KPNA2 and
KPNA2N expression on STAT1/GFP localization to control
for potential nuclear import effects associated with plasmid
expression of a karyopherin. Flag-tagged KPNA2 and STAT1/
GFP were localized in Vero cells before and after the addition
of IFN-. Prior to IFN treatment, STAT1 is localized to the
cytoplasm, and KPNA2 is located predominately in the nucleus
(Fig. 6B). After IFN treatment, STAT1 efficiently localizes to
the nucleus in the presence or absence of Flag-tagged KPNA2
(Fig. 6B). Transfection of Flag-tagged KPNA2N and STAT1/
GFP indicated that STAT1 was localized in the cytoplasm
before IFN- treatment; however, KPNA2N was localized to
both the cytoplasm and, to a lesser extent, the nucleus (Fig. 6C,
D, and E). This agrees with biochemical studies suggesting that
KPNA2N is impaired for KPNB1 binding and less efficiently
imported to the nucleus. After IFN- treatment, STAT1 effi-
ciently localizes to the nucleus as before.
As shown by immunoprecipitation, KPNA2N binds ORF6
but no longer binds KPNB1. If KPNB1 recruitment to the
ER/Golgi membrane limits STAT1 nuclear localization, then
KPNA2N expression in the presence of ORF6 should not
block STAT1 nuclear localization in the cell. We find that the
cotransfection of STAT1/GFP, wild-type KPNA2, and ORF6
blocks STAT1 nuclear localization after IFN- treatment
(Fig. 6D). Interestingly, the cotransfection of STAT1/GFP,
KPNA2N, and ORF6 did not block STAT1 nuclear localiza-
tion after IFN- treatment (Fig. 6E). STAT1 was efficiently
imported into the nucleus in those cells. These data demon-
strate that KPNB1:KPNA2:ORF6 complex formation was nec-
essary to inhibit STAT1 nuclear transport.
The C-terminal tail of ORF6 binds to KPNA2. Based on
structural predictions, the C terminus of ORF6 was predicted to
protrude from the ER/Golgi membrane into the cytoplasm (struc-
ture algorithm from http://bp.nuap.nagoya-u.ac.jp/sosui/). We hy-
pothesized that the C terminus of ORF6 may be interacting with
the karyopherins and constructed a series of alanine mutations in
the C terminus of ORF6 to more precisely map the ORF6 region
necessary for antagonist activity. Amino acids 49 to 53, 54 to 58,
and 59 to 63 of ORF6 were independently mutated to alanine
(Fig. 7A). When fused to GFP, each product localized to the
ER/Golgi membrane similarly to wild-type ORF6 (Fig. 7B).
After cotransfection with STAT1-GFP into Vero cells, ORF6
with amino acids 49 to 53 mutated to Ala (ORF649-53Ala), but
not ORF654-58Ala or ORF659-63Ala, was able to block STAT1
nuclear transport after the addition of IFN- (Fig. 7C). We
further characterized the alanine mutants by determining
whether KPNA2 would be retained in the ER/Golgi membrane.
Under conditions in which ORF654-58Ala and ORF659-63Ala did
not retain KPNA2, the ORF649-53Ala product still retained
KPNA2 at the ER/Golgi membrane by confocal microscopy
(Fig. 8). These data demonstrate that the C-terminal 10 amino
acids of ORF6 are critical for KPNA2 binding and STAT1
blockage.
DISCUSSION
Viruses have evolved diverse mechanisms to evade host in-
nate and adaptive immunity (1, 2, 4, 6, 16, 19, 20, 30–32, 37, 41,
49). SARS-CoV infection does not induce type I IFN in most
cells in culture and likely encodes several proteins that disrupt
IFN production. In support of data from previous work (25),
we show that SARS-CoV encoding a functional ORF6 protein
was able to block STAT1-mediated signaling, while deletion
mutants lacking ORF6 could not block STAT1 translocation
into the nucleus after IFN treatment. SARS infection also
retains KPNA2 at the ER/Golgi membrane; however, in
SARSORF6-infected cells, KPNA2 resides in the nucleus.
ORF6 also retained KPNB1 at the ER/Golgi membrane in
complex with KPNA2. Deletion of the N terminus of KPNA2,
which binds KPNB1, no longer retained KPNB1 at the ER/
Golgi membrane in the presence of ORF6 and did not antag-
onize STAT1 nuclear import in response to IFN-.
Under normal conditions, the NLS:KPNA2 interaction re-
veals an importin beta binding motif at the N terminus of
KPNA2 which binds KPNB1. This complex is then imported
VOL. 81, 2007 SARS-COV ORF6 IS AN IFN ANTAGONIST 9819
into the nucleus, where Ran-GTP induces the release of
KPNA2 and KPNB1 from the cargo, and it is recycled back out
into the cytoplasm and able to bind to new cargo. Our working
model is that the cytoplasmic tail of ORF6, acting as a mock
NLS, functions to bind and retain KPNA2 on the ER/Golgi
membrane (Fig. 9). Since membrane-bound ORF6 is unable to
be imported into the nucleus, KPNA2 is retained in a bound
state with a functionally exposed importin beta binding domain
at its N terminus. Although the importin beta binding domain
recruits and binds KPNB1, the complex cannot localize to the
nucleus and remains tethered in a bound state. Since the levels
of Ran-GTP are very low in the cytoplasm, KPNB1 and
KPNA2 cannot release the bound ORF6 cargo and are func-
tionally retained at the ER/Golgi membrane.
ORF6 and innate immunity. Unlike other IFN antagonists
that have cytoplasmic localizations (for example, Ebola virus
FIG. 6. KPNA2 interactions with ORF6 and KPNB1. (A) 293 cells were transfected with either Flag-tagged KPNA1, KPNA2, or KPNA2N
in combination with HA-tagged ORF6. At 24 h after transfection, cells were treated with 100 IU/ml IFN- for 30 min, and lysates were collected.
Proteins were immunoprecipitated (IP) with anti-Flag antibodies as described in Materials and Methods. Immunoprecipitated extracts were then
separated on a 4 to 12% SDS-PAGE gel and analyzed by Western blot (WB) probed with anti-HA, anti-KPNB1, anti-STAT1, and anti-Flag
antibodies. Whole-cell extracts (WCL) were also blotted for ORF6 transfection with anti-HA antibodies. (B and C) Vero cells were transfected
with STAT1/GFP and either Flag-tagged KPNA2 or KPNA2N. At 24 h posttransfection, cells were treated with 100 IU/ml IFN- for 60 min
before fixation. Proteins were visualized with anti-Flag (FLAG) antibodies and for the presence of GFP using confocal microscopy. (D and E)
Vero cells were transfected as described above (B) except for the addition of HA-tagged ORF6. Cells were stained with anti-Flag and anti-HA
antibodies and visualized using confocal microscopy for Flag (Alexa Fluor 546)-, HA (Alexa Fluor 633)-, and GFP-tagged proteins.
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VP24 [47] and VP35 [2], Nipah virus V [53], and hepatitis C
virus [19]), ORF6 is uniquely localized to the ER/Golgi mem-
brane. ORF6 binds to KPNA2, retargeting its localization from
the cytoplasm to the ER/Golgi membrane. Although KPNA2
does not participate directly in STAT1 import, the retention of
KPNA2 on the ER/Golgi membrane and the subsequent re-
cruitment of KPNB1 to the ER/Golgi membrane as well prob-
ably deplete KPNB1 concentrations in the cytoplasm, retard-
ing the translocation of the STAT1:KPNA1 complex from
entering the nucleus. In virus-infected but not uninfected cells,
ORF6 expression should block STAT1 signaling in the context
of either autocrine or paracrine signaling, suggesting that the
SARS-CoV-infected cell would be highly resistant to IFN and
provide a protected environment for efficient SARS-CoV rep-
lication. Experiments examining the dynamics of STAT1 local-
ization in icSARS-CoV and icSARSORF6 during in vivo
infection in mice are in progress. The ORF6:KPNA2:KPNB1
interaction also has the potential to simultaneously antagonize
several innate immune pathways in infected cells. Reductions
in the concentration of free cytoplasmic KPNB1 pools would
reduce the rate of KPNA- and KPNB-mediated transport as
well as their cargo involved in innate immune responses to viral
infection (e.g., AP-1, IRF3, IRF7, and STAT1) (8). KPNA2
also imports other cargo into the nucleus of cells, a function
that is likely antagonized by ORF6. For example, NF-B uses
KPNA2 for nuclear transport (10), and we have shown that
NF-B-inducible genes are poorly induced during SARS in-
fection in vitro (15).
ORF6 and nucleocytoplasmic shuttling. Cytoplasmic pro-
tein levels of KPNB1 have been shown to be important for the
rapid kinetics of NLS-containing cargo. Changes in the levels
of injected KPNB1 in cells can drastically modify the nuclear
FIG. 7. C-terminal mutations of ORF6 affect STAT1 localization.
(A) Schematic of ORF6 alanine mutants expressed in B to D. Numbers
correspond to amino acids in ORF6. The black box indicates the amino
acids that are changed to alanine in the protein (B) Each alanine
mutant was fused to a C-terminal GFP and expressed in Vero cells.
Localization is shown via a GFP filter on a confocal microscope.
(C) Each HA-tagged alanine mutant was cotransfected with STAT1/
GFP. At 24 h posttransfection, cells were treated with 100 IU/ml of
IFN- for 60 min before fixation in 4% PFA. STAT1/GFP was visu-
alized on a confocal microscope.
FIG. 8. C-terminal mutations of ORF6 affect karyopherin localiza-
tion. (A) HA-tagged alanine scanning mutants of ORF6 (as described in
the text) were cotransfected with either Flag-tagged KPNA1 or KPNA2.
At 24 h posttransfection, cells were fixed and labeled with anti-HA and
anti-Flag antibodies. Cells were visualized using a confocal microscope for
Alexa Fluor 488 and Alexa Fluor 546 fluorescence.
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import kinetics of a protein (59). Yang and Musser found that
under conditions of low KPNB1 protein concentration, only
50% of the nuclear pore-associated cargos are imported into
the nucleus, yet with high concentrations of KPNB1, 80% of
the cargo is imported into the nucleus and with a sevenfold-
faster transit (59). Alterations of the free KPNB1 concentra-
tion in the cytoplasm by ORF6 may mimic the lower concen-
tration of KPNB1 seen in those experiments and explain the
diminished STAT1 nuclear translocation.
Our data predict that the relative concentrations of ORF6,
KPNB1, and KPNA2 within an infected cell will influence the
efficiency of the ORF6-STAT1 antagonistic activity. SARS-CoV
infection has been reported in bronchial epithelium, type I and II
pneumocytes, T lymphocytes, macrophages/monocytes, fibro-
blasts, vascular endothelial cells, epithelial mucosa of the intes-
tine, and neurons. Karyopherins, especially KPNA2, are differen-
tially expressed in different tissues and cell types in vivo (39). The
antagonistic activity of SARS-CoV ORF6 may be ineffective in
some virus-infected tissues due to lower KPNA2 expression lev-
els. One possible explanation for the finding that SARS infection
of plasmacytoid (pDC), but not conventional dendritic cells, in-
duced large amounts of IFN (5) may be related to the levels of
karyopherins. If there are low levels of KPNA2 in a cell, the effect
of ORF6 to block STAT1 will be diminished. Alternatively, var-
ious levels of ORF6 and other SARS IFN antagonists may be
expressed in different cell types. For example, SARS-CoV infec-
tion in macrophages and dendritic cells has been characterized by
low levels of viral gene expression and the release of few viral
progeny (5). If the SARS-CoV IFN antagonists are not expressed
at high enough levels in those cell types, their ability to block the
IFN sensing or signaling pathways would be diminished, leading
to increased IFN production.
SARS-CoV infection is most severe in the elderly (3, 13, 29,
42). Karyopherin expression varies with the age of the cell as
well (46). In fact, nuclear import/export-associated KPNA2,
Ran binding protein 1, and cellular apoptosis susceptibility (an
exportin) mRNAs are found to be down-regulated in fibro-
blasts from old donors compared to fibroblasts from young
donors (46). In this study, old human fibroblasts further
showed reduced import rates of a reporter protein compared
to those of young donor fibroblasts, suggesting that older cells
and, by analogy, older individuals may be more susceptible to
SARS due to altered nuclear import/export machinery levels.
Recently, it has been shown that SARS infection of senescent
mice increases pathogenesis and weight loss in comparison to
young mice (12, 58). Senescent mice show increased viral titers
and lung pathology, suggesting that altered nuclear import
FIG. 9. Model for ORF6 function. Upon IFN- or - stimulation of the IFN receptor on the surface of a cell, the STAT1:STAT2:IRF9 complex
is formed. The NLS formed from STAT1 and STAT2 is recognized by KPNA1 (K1) for import into the nucleus. SARS-CoV-infected cells that
are ER/Golgi membrane localized (shown here only on the ER membrane for clarity) bind to KPNA2, which recruits KPNB1 to the membrane
complex as well. This creates a concentration-dependent competition between the ORF6:KPNA2 and ISGF3:KPNA1 complexes for the free
unbound KPNB1 in the cytoplasm. This depletion of free KPNB1 in the cytoplasm produces a block in import of the ISGF3 complex in response
to both IFN- and IFN-	 and leaves KPNB1 bound to KPNA2 and ORF6 on the ER/Golgi membrane.
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mechanics may contribute to a less developed and robust in-
nate and adaptive immune response.
ORF6 and pathogenesis. Previous work has shown that the
insertion of ORF6 into a nonvirulent strain of MHV resulted
in disease enhancement and death in a mouse model of MHV
(44). Tangudu et al. further showed that ORF6 accelerates the
replication of MHV, a phenotype that may contribute to in-
creased lethality in mice (57). Those data, in agreement with
our findings, support the hypothesis that ORF6 is an important
virulence protein during in vivo infection. Although the mech-
anism of action in the MHV backbone is unknown, it seems
plausible that ORF6 antagonism of the KPNA2 import ma-
chinery is a likely possibility. In those studies, however, ORF6
was expressed from a relatively weak mRNA 4 transcription
regulatory sequence, so it will be very important to carefully
evaluate and compare levels of ORF6 expression in heterolo-
gous (MHV) and homologous (SARS-CoV) genome back-
bones because the abundance of product correlates with
STAT1 antagonism. We are currently investigating the role of
ORF6 in in vivo pathogenesis using our deletion virus and the
mouse-adapted SARS-CoV model (48).
Consonant with the findings reported in this paper, STAT1
knockout mice are unable to clear SARS-CoV infection. Virus
titers remain high, and infection rapidly disseminates from the
lungs to the liver and spleen, demonstrating the importance of
the STAT1 pathway in regulating disease severity in vivo (21).
Although the removal of STAT1 leads to increased SARS-
CoV-induced disease, this does not preclude virus-mediated
antagonism of STAT1. ORF6 mediated the antagonism of
STAT1, which, unlike the knockout animal, is unlikely to be
100% efficient and probably functions to attenuate signaling
by type I and type II IFNs in infected cells, thereby promot-
ing viral replication and spread. An ORF6 block in type I
and type II IFN amplification in infected tissue will greatly
diminish the amplification of the IFN signal to surrounding
cells. Therefore, additional studies to assess the contribu-
tion of ORF6 to the in vivo pathogenesis of SARS-CoV will
be extremely important.
The mechanism by which ORF6 antagonizes the IFN signaling
pathway via nuclear import machinery may well be an unexplored
commonality of many diverse viruses, with each virus having its
own mechanism of inhibiting nuclear import (for example, Ebola
virus VP24 versus SARS-COV ORF6). Compared with antago-
nists that target individual cargo and signaling cascades, the per-
turbation of nuclear import machinery may affect a broader range
of host signaling networks and contribute significantly to in-
creased pathogenesis. The identification of other viral proteins
inhibiting similar pathways will contribute to our understanding of
the mechanisms responsible for the pathogenesis of SARS-CoV,
identify novel viral drug targets, and provide essential tools to
investigate nuclear import.
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